Fonte: Drug Metabolism Personalized Theraphy. Unidade: FCF
Assuntos: POLIMORFISMO, TRANSPLANTE DE RIM
ABNT
TAMASHIRO, Erika Yumi et al. Influence of CYP3A4 and CYP3A5 polymorphisms on tacrolimus and sirolimus exposure in stable kidney transplant recipients. Drug Metabolism Personalized Theraphy, v. 32, n. 2, p. 89-95, 2017Tradução . . Disponível em: https://doi.org/10.1515/dmpt-2016-0036. Acesso em: 16 nov. 2024.APA
Tamashiro, E. Y., Felipe, C. R., Genvigir, F. D. V., Rodrigues, A. C., Campos, A. B., Hirata, R. D. C., et al. (2017). Influence of CYP3A4 and CYP3A5 polymorphisms on tacrolimus and sirolimus exposure in stable kidney transplant recipients. Drug Metabolism Personalized Theraphy, 32( 2), 89-95. doi:10.1515/dmpt-2016-0036NLM
Tamashiro EY, Felipe CR, Genvigir FDV, Rodrigues AC, Campos AB, Hirata RDC, Silva Junior HT, Pestana JOM. Influence of CYP3A4 and CYP3A5 polymorphisms on tacrolimus and sirolimus exposure in stable kidney transplant recipients [Internet]. Drug Metabolism Personalized Theraphy. 2017 ; 32( 2): 89-95.[citado 2024 nov. 16 ] Available from: https://doi.org/10.1515/dmpt-2016-0036Vancouver
Tamashiro EY, Felipe CR, Genvigir FDV, Rodrigues AC, Campos AB, Hirata RDC, Silva Junior HT, Pestana JOM. Influence of CYP3A4 and CYP3A5 polymorphisms on tacrolimus and sirolimus exposure in stable kidney transplant recipients [Internet]. Drug Metabolism Personalized Theraphy. 2017 ; 32( 2): 89-95.[citado 2024 nov. 16 ] Available from: https://doi.org/10.1515/dmpt-2016-0036